Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PIRACETAM IN PATIENTS WITH CHRONIC VERTIGO - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Autore:
ROSENHALL U; DEBERDT W; FRIBERG U; KERR A; OOSTERVELD W;
Indirizzi:
UCB PHARMA,INT DEV,CHEMIN FORIEST B-1420 BRAINE LALLEUD BELGIUM UCB PHARMA,INT DEV B-1420 BRAINE LALLEUD BELGIUM KAROLINSKA HOSP,DEPT AUDIOL S-10401 STOCKHOLM SWEDEN UNIV UPPSALA HOSP,DEPT ENT UPPSALA SWEDEN ROYAL VICTORIA HOSP BELFAST BT12 6BA ANTRIM NORTH IRELAND UNIV AMSTERDAM,MED CTR,DEPT ENT AMSTERDAM NETHERLANDS
Titolo Testata:
Clinical drug investigation
fascicolo: 5, volume: 11, anno: 1996,
pagine: 251 - 260
SICI:
1173-2563(1996)11:5<251:PIPWCV>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
23
Recensione:
Indirizzi per estratti:
Citazione:
U. Rosenhall et al., "PIRACETAM IN PATIENTS WITH CHRONIC VERTIGO - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY", Clinical drug investigation, 11(5), 1996, pp. 251-260

Abstract

The nootropic agent piracetam, which exerts diverse effects through actions on cerebral neurotransmission, has been reported to alleviate vertigo. We performed a multicentre, double-blind, placebo-controlled study to assess the efficacy and tolerability of piracetam 800mg 3 times daily orally for 8 weeks. The study group consisted of 143 middle-aged and elderly outpatients of ear, nose and throat clinics who had suffered from vertigo for at least 3 months, had experienced at least 3 episodes per month, and the vertigo was severe enough to disrupt daily life. Primary outcome measures were patient self-evaluations of vertigo: the frequency of episodes, and their severity using visual analoguescales (VAS). Malaise and imbalance between episodes (VAS), the effect of vertigo on walking (VAS), the duration of incapacity, and overallevaluations by patients and investigators were also assessed. On entry, episodes were more frequent (p < 0.05) and malaise between episodesmore severe (p < 0.05) in the piracetam group. Data were not evaluable in 54 patients because of either adverse events (12 piracetam, 12 placebo) or protocol deviations. An intention-to-treat analysis showed that episodes of vertigo were less frequent (p < 0.03) but not less severe on piracetam than on placebo: interval malaise (p < 0.05) and imbalance (p < 0.01) improved more and the duration of incapacity was less(p < 0.05). These changes, which were maximal after 8 weeks' medication, had almost disappeared 4 weeks after the end of treatment. Tolerance to piracetam was good, with few drug-related adverse events occurring. These findings provide further evidence that piracetam alleviates vertigo by reducing the frequency of episodes, the severity of malaiseand imbalance between episodes, and the duration of associated incapacity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 01:36:03